Vaccines

Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management

This collection of insights, produced through a partnership between

Merck KGaA, Darmstadt, Germany
,
MilliporeSigma
and Bioprocess Online, highlights strategies and guidance to ensure reliable biomanufacturing capacity and supply chains for the delivery of health technologies like vaccines, even during crisis conditions.

On demand Webinar mRNA – POWERING LIFE CHANGING THERAPIES

In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and process efficiency from preclinical to commercial.

Improved endotoxin removal using ecofriendly detergents for intensified plasmid capture

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with analytical in-process control assays, and overall process compatibility, and this comprehensive screening approach provides valuable insights to intensified plasmids production.

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?

Post Pandemic: How a new era of supplier-vender collaboration is transforming Biopharma

Check out this article where

Merck
MilliporeSigma
‘s Eva Schaefer, Director of Supply Robustness, and Tom Elich, MSAT Manager, discuss how industry collaboration has never been more important.

Strengthening the CDMO-Sponsor Partnership with Improved Data Sharing and Collaboration

Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous and asynchronous data and how a data integration platform can improve project lifecycle data management, and collaborative data sharing.

Bioprocessing operators in a closed processing CNC space

Are you OPEN to CLOSE your bioprocess?

In this webinar, you will:
•Understand the main drivers and benefits of closed processing in biopharma, including facility utilization, sustainability, cost reductions, and labor savings.
•Analyze biopharma facility design, comparing traditional layouts to innovative, modular, and ballroom-style configurations.
•Learn about industry guidance and best practices in the adoption of closed processing.

Neglected Tropical Diseases — Improving the Manufacturing Paradigm for a Novel Recombinant Protein Vaccine

Vaccine Development collaboration: from Schistosomiasis to COVID-19 vaccine.

What if you could enable upstream intensification of your process?

In this webinar, you will learn how our new single-use bioreactor family can help you:
– Fulfill any process strategy, be it batch, fed-batch or perfusion
– Facilitate scalability of your upstream process
– Utilize the flexible design to reduce production costs

Optimize Vaccine Production with Templated Processes

A wide range of novel vaccine modalities and conventional approaches are used to prevent and reduce the impact of infection. Adoption of templated manufacturing processes tailored to the specific modality can optimize and accelerate production workflows.

Scroll to Top